Department of Medicine, Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
Semin Liver Dis. 2021 Jan;41(1):9-18. doi: 10.1055/s-0040-1722261. Epub 2021 Jan 14.
Tumor heterogeneity, a key hallmark of hepatocellular carcinomas (HCCs), poses a significant challenge to developing effective therapies or predicting clinical outcomes in HCC. Recent advances in next-generation sequencing-based multi-omic and single cell analysis technologies have enabled us to develop high-resolution atlases of tumors and pull back the curtain on tumor heterogeneity. By combining multiregion targeting sampling strategies with deep sequencing of the genome, transcriptome, epigenome, and proteome, several studies have revealed novel mechanistic insights into tumor initiation and progression in HCC. Advances in multiparametric immune cell profiling have facilitated a deeper dive into the biological complexity of HCC, which is crucial in this era of immunotherapy. Moreover, studies using liquid biopsy have demonstrated their potential to circumvent the need for tissue sampling to investigate heterogeneity. In this review, we discuss how multi-omic and single-cell sequencing technologies have advanced our understanding of tumor heterogeneity in HCC.
肿瘤异质性是肝细胞癌 (HCC) 的一个关键特征,这给开发有效的治疗方法或预测 HCC 的临床结果带来了重大挑战。基于下一代测序的多组学和单细胞分析技术的最新进展使我们能够开发出肿瘤的高分辨率图谱,并深入了解肿瘤异质性。通过将多区域靶向采样策略与基因组、转录组、表观基因组和蛋白质组的深度测序相结合,几项研究揭示了 HCC 中肿瘤发生和进展的新机制见解。多参数免疫细胞分析的进展促进了对 HCC 生物学复杂性的更深入研究,这在免疫治疗时代至关重要。此外,使用液体活检的研究表明,它们有可能避免组织采样来研究异质性。在这篇综述中,我们讨论了多组学和单细胞测序技术如何提高我们对 HCC 中肿瘤异质性的理解。